文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

临床药师主导的骨科创伤患者静脉血栓栓塞预防全程管理模式:随机对照试验方案

Development and evaluation of a clinical pharmacist-led full-course management model for venous thromboembolism prophylaxis in orthopedic trauma patients: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2026-02-10

干预组接受药师主导的全程管理,包括Caprini评分、出血风险评估、用药核对、教育、剂量优化、不良事件监测及出院后电话随访;对照组接受标准医疗。主要结局为术后90天内症状性和无症状性VTE发生率。

要点

  • 临床药师主导的全程管理可能改善骨科创伤患者VTE预防效果。
  • 主要结局为术后90天内症状性和无症状性VTE发生率。
  • 该试验旨在为药师主导管理模式提供高质量证据。

核心结论

  • 该随机对照试验旨在评估临床药师主导的全程管理模式对骨科创伤患者VTE预防效果的影响。

关键数值与推荐

  • 干预组接受药师主导的全程管理,包括个体化VTE风险(Caprini评分)和出血风险评估、用药核对、患者教育、剂量优化、不良事件监测及出院后第21、35、90天电话随访。
  • 主要结局为术后90天内症状性和无症状性VTE发生率;次要结局包括大出血和临床相关非大出血事件发生率及用药依从性(用药持有率)。
  • 数据分析采用意向性治疗原则。

临床怎么用

  • 若证实有效,临床药师主导的全程管理模式可整合入骨科创伤患者VTE预防路径。

局限性

  • 该研究为单中心设计,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is a common and potentially fatal complication in orthopedic trauma patients, particularly following lower limb and hip-related fractures. While pharmacological prophylaxis is the cornerstone of prevention for patients at moderate to high risk, its use is a balance between efficacy and bleeding risk. Clinical pharmacists play an increasingly important role in optimizing pharmacotherapy, but evidence for the effectiveness of a comprehensive, pharmacist-led management model spanning both inpatient and outpatient care for VTE prophylaxis in this population is scarce. METHODS: This is a single-center, prospective, randomized controlled trial. One hundred seventy eligible orthopedic trauma patients at risk for VTE will be randomly allocated in a 1:1 ratio to either the intervention group or the control group. The intervention group will receive a pharmacist-led, full-course management model, which includes personalized VTE risk (Caprini score) and bleeding risk assessment, medication reconciliation, patient education, dosing optimization, adverse event monitoring, and structured follow-up via telephone at 21, 35, and 90 days post-discharge. The control group will receive standard medical care without this structured pharmacist intervention. The primary outcome is the incidence of symptomatic and asymptomatic VTE within 90 days post-surgery. Secondary outcomes include the incidence of major and clinically relevant non-major bleeding events, medication adherence (measured by Medication Possession Ratio). Data will be analyzed on an intention-to-treat basis. DISCUSSION: This randomized controlled trial aims to generate high-quality evidence on the effectiveness of a clinical pharmacist-led management model for improving outcomes in orthopedic trauma patients requiring VTE prophylaxis. TRIAL REGISTRATION: The study has been registered in the Chinese Clinical Trial Registry (retrospectively registered no. ChiCTR2500107932) on 21 August 2025, at https://www.chictr.org.cn/showproj?proj=279391 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ni R, Huang P, Gao Z, et al. Development and evaluation of a clinical pharmacist-led full-course management model for venous thromboembolism prophylaxis in orthopedic trauma patients: study protocol for a randomized controlled trial. Trials. 2026. PMID: 41668166. doi:10.1186/s13063-026-09478-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。